Benin Management increased its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 29.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The hedge fund owned 5,441 shares of the biopharmaceutical company’s stock after buying an additional 1,234 shares during the period. Benin Management’s holdings in Bristol-Myers Squibb were worth $374,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of BMY. CIBC World Markets raised its position in shares of Bristol-Myers Squibb by 23.4% in the fourth quarter. CIBC World Markets now owns 280,646 shares of the biopharmaceutical company’s stock valued at $19,306,000 after buying an additional 53,260 shares during the last quarter. First American Bank raised its position in shares of Bristol-Myers Squibb by 2.5% in the fourth quarter. First American Bank now owns 27,180 shares of the biopharmaceutical company’s stock valued at $1,870,000 after buying an additional 668 shares during the last quarter. Quotient Investors bought a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at $420,000. Atria Investments raised its position in shares of Bristol-Myers Squibb by 9.5% in the fourth quarter. Atria Investments now owns 26,362 shares of the biopharmaceutical company’s stock valued at $1,677,000 after buying an additional 2,293 shares during the last quarter. Finally, Jacobs & Company raised its position in shares of Bristol-Myers Squibb by 0.9% in the fourth quarter. Jacobs & Company now owns 22,578 shares of the biopharmaceutical company’s stock valued at $1,432,000 after buying an additional 210 shares during the last quarter.

Bristol-Myers Squibb Co (NYSE:BMY) traded down 0.05% on Thursday, hitting $61.68. 8,079,399 shares of the stock were exchanged. The firm has a market cap of $102.90 billion and a PE ratio of 58.08. The company has a 50-day moving average price of $66.37 and a 200-day moving average price of $64.50. Bristol-Myers Squibb Co has a 52-week low of $51.82 and a 52-week high of $70.87.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, January 28th. The biopharmaceutical company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.10. The firm earned $4.29 billion during the quarter, compared to the consensus estimate of $4.07 billion. Bristol-Myers Squibb’s revenue for the quarter was up .7% compared to the same quarter last year. During the same quarter last year, the company posted $0.46 EPS. On average, equities research analysts anticipate that Bristol-Myers Squibb Co will post $1.91 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Monday, February 1st. Stockholders of record on Monday, January 4th will be paid a $0.38 dividend. The ex-dividend date of this dividend is Wednesday, December 30th. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.35. This represents a $1.52 dividend on an annualized basis and a dividend yield of 2.46%.

BMY has been the topic of several research reports. Vetr upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $69.74 price target on the stock in a research note on Wednesday. Credit Suisse restated an “outperform” rating on shares of Bristol-Myers Squibb in a research note on Monday. BMO Capital Markets downgraded shares of Bristol-Myers Squibb from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $74.00 to $70.00 in a research note on Monday. They noted that the move was a valuation call. Leerink Swann restated a “buy” rating on shares of Bristol-Myers Squibb in a research note on Friday, January 22nd. Finally, Berenberg Bank upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $77.00 price target on the stock in a research note on Friday, January 22nd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $73.93.

In other news, Director Lamberto Andreotti sold 11,600 shares of the stock in a transaction on Monday, January 4th. The stock was sold at an average price of $66.93, for a total value of $776,388.00. Following the sale, the director now directly owns 310,424 shares of the company’s stock, valued at $20,776,678.32. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Bristol-Myers Squibb Company (NYSE:BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The Company manufactures its products in the United States, Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers, such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print, radio, television, and digital advertising and promotion. In addition, the Company holds rights to F001287, which is a preclinical, small-molecule IDO1-inhibitor.

12 Month Chart for NYSE:BMY

Receive News & Ratings for Bristol-Myers Squibb Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co and related companies with MarketBeat.com's FREE daily email newsletter.